915070-53-0 Usage
Uses
Used in Pharmaceutical Industry:
2-Chloro-3-methylphenylboronic acid is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to facilitate the formation of complex molecular structures through cross-coupling reactions. It aids in the development of new drugs with potential therapeutic applications, enhancing the discovery and innovation of life-saving medications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloro-3-methylphenylboronic acid is employed as a reagent in the synthesis of agrochemicals, contributing to the production of effective pesticides and other crop protection agents. Its role in forming carbon-carbon and carbon-heteroatom bonds is crucial for creating molecules with the desired biological activity to protect crops from pests and diseases.
Used in Organic Synthesis:
2-Chloro-3-methylphenylboronic acid is utilized as a versatile reagent in organic synthesis for its capacity to participate in various cross-coupling reactions. This allows chemists to construct a wide range of organic compounds, including those with specific biological activities or unique structural features, broadening the scope of chemical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 915070-53-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,5,0,7 and 0 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 915070-53:
(8*9)+(7*1)+(6*5)+(5*0)+(4*7)+(3*0)+(2*5)+(1*3)=150
150 % 10 = 0
So 915070-53-0 is a valid CAS Registry Number.
915070-53-0Relevant academic research and scientific papers
Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2
-
Paragraph 0502-0504, (2019/03/30)
The present invention relates to compounds capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds, and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
